Efficacy of antibody-based therapies to treat Alzheimer's disease: Just a matter of timing?

Experimental Gerontology

Volumn 57, Issue , 2014, Pages 104-106

  Cedernaes, Jonathan ^a   Schiöth, Helgi B ^a   Benedict, Christian ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Antibody based therapy; Cognitive decline; Lifestyle factors; Phase III clinical trials

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BAPINEUZUMAB; SOLANEZUMAB; TAU PROTEIN; ANTIBODY; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; AMYLOID PLAQUE; COGNITIVE THERAPY; DISEASE COURSE; DRUG EFFICACY; EXERCISE; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; MENTAL CAPACITY; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CAPACITY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; IMMUNOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY;

EID: 84901661940     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2014.05.002     Document Type: Note

References (19)

1. Benedict C., Cedernaes J., Giedraitis V., Nilsson E.K., Hogenkamp P.S., Vagesjo E., Massena S., Pettersson U., Christoffersson G., Phillipson M., Broman J.E., Lannfelt L., Zetterberg H., Schioth H.B. Acute sleep deprivation increases serum levels of neuron-specific enolase (NSE) and S100 calcium binding protein B (S-100B) in healthy young men. Sleep 2014, 37:195-198.
2. Blennow K., Zetterberg H., Rinne J.O., Salloway S., Wei J., Black R., Grundman M., Liu E. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 2012, 69:1002-1010. AAB-001 201/202 Investigators.
3. Devanand D.P., Mikhno A., Pelton G.H., Cuasay K., Pradhaban G., Dileep Kumar J.S., Upton N., Lai R., Gunn R.N., Libri V., Liu X., van Heertum R., Mann J.J., Parsey R.V. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J. Geriatr. Psychiatry Neurol. 2010, 23:185-198.
4. Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., Forster S., Winter Y., Bach J.P., Popp J., Alferink J., Wiltfang J., Buerger K., Otto M., Antuono P., Jacoby M., Richter R., Stevens J., Melamed I., Goldstein J., Haag S., Wietek S., Farlow M., Jessen F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013, 12:233-243.
5. Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., Raman R., Sun X., Aisen P.S., Siemers E., Liu-Seifert H., Mohs R. For the Alzheimer's Disease Cooperative Study Steering Committee and the Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370:311-321.
6. Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P., Friedrich S., Dean R.A., Gonzales C., Sethuraman G., DeMattos R.B., Mohs R., Paul S.M., Siemers E.R. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers. Dement. 2012, 8:261-271.
7. Hahn E.A., Wang H.X., Andel R., Fratiglioni L. A change in sleep pattern may predict Alzheimer disease. Am. J. Geriatr. Psychiatry. 2013 Aug 13, pii: S1064-7481(13)00233-9. [Epub ahead of print]. 10.1016/j.jagp.2013.04.015.
8. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
9. Laske C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med. 2014, 370:1459.
10. PubMed. 2014 (Accessed on May 4).
11. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., Rodriguez Martinez de Liano S., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
12. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
13. Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M., Sabbagh M., Honig L.S., Porsteinsson A.P., Ferris S., Reichert M., Ketter N., Nejadnik B., Guenzler V., Miloslavsky M., Wang D., Lu Y., Lull J., Tudor I.C., Liu E., Grundman M., Yuen E., Black R., Brashear H.R. Bapineuzumab; clinical trial, I. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370:322-333.
14. Salloway S., Sperling R., Brashear H.R. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med. 2014, 370:1460.
15. Savonenko A.V., Melnikova T., Hiatt A., Li T., Worley P.F., Troncoso J.C., Wong P.C., Price D.L. Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology 2012, 37:261-277.
16. Sperling R., Salloway S., Brooks D.J., Tampieri D., Barakos J., Fox N.C., Raskind M., Sabbagh M., Honig L.S., Porsteinsson A.P., Lieberburg I., Arrighi H.M., Morris K.A., Lu Y., Liu E., Gregg K.M., Brashear H.R., Kinney G.G., Black R., Grundman M. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012, 11:241-249.
17. Verghese J., Lipton R.B., Katz M.J., Hall C.B., Derby C.A., Kuslansky G., Ambrose A.F., Sliwinski M., Buschke H. Leisure activities and the risk of dementia in the elderly. N. Engl. J. Med. 2003, 348:2508-2516.
18. World Health Organization and Alzheimer's Disease International Dementia: A Public Health Priority 2012.
19. Xie L., Kang H., Xu Q., Chen M.J., Liao Y., Thiyagarajan M., O'Donnell J., Christensen D.J., Nicholson C., Iliff J.J., Takano T., Deane R., Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.